MajorMacrolide antibiotic×Atypical antipsychotic – active metabolite of risperidone
Updated · Methodology
Mechanism
Erythromycin prolongs the QT interval on the electrocardiogram, and torsade de pointes and deaths have been reported with it, including after intravenous use (erythromycin labels). Paliperidone also prolongs the corrected QT interval (QTc), and the European label lists QT prolongation among the most frequent adverse reactions in clinical trials (paliperidone labels). In a QT study, immediate-release paliperidone 8 mg increased QTc by a mean of 12.3 ms over placebo, at blood levels more than twice those of the maximum 12 mg extended-release dose (paliperidone label, US Food and Drug Administration, FDA). Taken together, the effects of the two drugs on the heart may add up. CYP enzymes play almost no part in paliperidone clearance. P-glycoprotein transports paliperidone, and erythromycin inhibits this transporter. The documents give no data on how erythromycin changes paliperidone levels (paliperidone and erythromycin labels).
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). The danger is ventricular arrhythmia: torsade de pointes, ventricular tachycardia, ventricular fibrillation and even cardiac arrest and sudden death (paliperidone and erythromycin labels). An arrhythmia episode presents as palpitations, dizziness or fainting. The risk is higher with bradycardia, low potassium or magnesium, congenital long QT syndrome, a family history of QT prolongation, heart disease and in older people (paliperidone and erythromycin labels).
Management
Avoid the combination: the US paliperidone label states that paliperidone prolongs the corrected QT interval (QTc) and should be avoided with other drugs that prolong QTc, antibiotics included (paliperidone label, US Food and Drug Administration, FDA). The Spanish label of one intravenous erythromycin product (Panpharma, registration number 79380) lists use with certain QT-prolonging neuroleptics among its contraindications. The labels of the original intravenous product and of oral forms ask only for caution with such drugs (erythromycin labels, Spanish Agency of Medicines and Medical Devices, AEMPS). The European paliperidone label also asks for caution with drugs that prolong the QT interval (paliperidone label, European Medicines Agency, EMA). Do not give erythromycin to patients with a history of QT prolongation or ventricular arrhythmia, including torsade de pointes, or with low potassium or magnesium (erythromycin labels, AEMPS). Avoid paliperidone in congenital long QT syndrome and in patients with a history of cardiac arrhythmia (paliperidone label, FDA). Use erythromycin with caution in coronary artery disease, severe heart failure, conduction disorders, clinically relevant bradycardia and in older people (erythromycin label, AEMPS). Check blood electrolytes when there is a risk of imbalance, for example with vomiting and diarrhoea or in patients taking diuretics (erythromycin label, AEMPS). Before prescribing erythromycin, weigh the benefit of treatment against the risk of cardiac complications (erythromycin labels, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Erythrocin Lactobionate-IV (erythromycin lactobionate for injection) – prescribing information (2025)– FDA label, Hospira, DailyMed setid a96c405f-bd70-4bb4-719e-ac6a79dcc213, version 25, 10/2025, CONTRAINDICATIONS (ergotamine, dihydroergotamine), WARNINGS (QT Prolongation), PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Eritromicina (nº registro 79380), sección 4.3 (2025)– AEMPS, CIMA, nº registro 79380, sección 4.3
- AEMPS: Ficha técnica: Eritromicina (nº registro 57474), sección 4.4 (2024)– AEMPS, CIMA, nº registro 57474 (Pantomicina 500 mg comprimidos), revisión 05/2024, secciones 4.3, 4.4 y 4.5
- FDA: E.E.S. (erythromycin ethylsuccinate) prescribing information (2025)– FDA, DailyMed, Carnegie Pharmaceuticals LLC, setid 91479d92-3bf3-4eb3-81bd-8ce4956d4347, revised 02/2025, Contraindications, Warnings – QT Prolongation, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión), revisión 09/2025, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Paliperidona (EU/1/07/395), sección 4.4 (2026)– EMA, Invega 3 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 107395041, consultada 10/2026, secciones 4.3, 4.4, 4.5, 4.8 y 4.9
- FDA: Invega (paliperidone) prescribing information (2025)– FDA, DailyMed, Janssen Pharmaceuticals, setid 7b8e5b26-b9e4-4704-921b-3c3c0d159916, version 43, effective 01/2025, sections 4, 5.4, 7.2 and 10